Sagent Pharmaceuticals,
Inc. SGNT today announced the reintroduction of Adenosine Injection,
USP, an antiarrhythmic agent, now in improved prefilled plastic syringes.
According to IMS, for the 12 months ending February 2014, the US market for
Adenosine Injection, USP approximated $28 million. As with all products in
Sagent's portfolio, Adenosine features Sagent's PreventIV Measures^SM
packaging and labeling, designed to help reduce medication errors.
About Adenosine Injection, USP
Adenosine Injection, USP is indicated for conversion to sinus rhythm of
paroxysmal supraventricular tachycardia (PSVT), including that associated with
accessory bypass tracts (Wolff-Parkinson-White Syndrome). When clinically
advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be
attempted prior to adenosine administration.
The package insert, available at www.sagentpharma.com, contains the
indications, complete side effect profile, and prescribing information.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on
developing, manufacturing, sourcing and marketing pharmaceutical products,
with a specific emphasis on injectables. Sagent has created a unique global
network of resources, comprising rapid development capabilities, sophisticated
manufacturing and innovative drug delivery technologies, resulting in an
extensive and rapidly expanding pharmaceutical product portfolio that fulfills
the evolving needs of patients.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in